文章：

自体CAR - t细胞疗法供应链：挑战与机遇？

Autologous CAR T-cell therapies supply chain: challenges and opportunities?

原文发布日期：2020-01-14 

英文摘要：

Chimeric antigen receptor (CAR) T cells are considered a potentially disruptive cancer therapy, showing highly promising results. Their recent success and regulatory approval (both in the USA and Europe) are likely to generate a rapidly increasing demand and a need for the design of robust and scalable manufacturing and distribution models that will ensure timely and cost-effective delivery of the therapy to the patient. However, there are challenging tasks as these therapies are accompanied by a series of constraints and particularities that need to be taken into consideration in the decision-making process. Here, we present an overview of the current state of the art in the CAR T cell market and present novel concepts that can debottleneck key elements of the current supply chain model and, we believe, help this technology achieve its long-term potential. 

摘要翻译： 

嵌合抗原受体（CAR）T细胞疗法被认为是一种具有潜在颠覆性的癌症治疗手段，其疗效显示出高度前景。该疗法近期取得的成功及在欧美获得的监管批准，预计将迅速推高市场需求，因此亟需建立稳健、可扩展的生产与分销模式，以确保治疗能够及时且成本高效地送达患者。然而，这一过程面临诸多挑战，因为此类疗法伴随一系列限制条件与特殊性，需要在决策过程中予以充分考虑。本文概述了CAR T细胞市场的当前发展现状，并提出了创新理念以解决现有供应链模式中的关键瓶颈问题。我们相信，这些举措将有助于该技术实现其长期潜力。

原文链接：

Autologous CAR T-cell therapies supply chain: challenges and opportunities?